Intravenous versus subcutaneous immunoglobulin replacement in secondary hypogammaglobulinemia

Clinical Immunology

Volumn 166-167, Issue , 2016, Pages 103-104

  Spadaro, Giuseppe ^a   Pecoraro, Antonio ^a   De Renzo, Amalia ^a   Della Pepa, Roberta ^a   Genovese, Arturo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN G; RITUXIMAB; IMMUNOLOGIC FACTOR;

GASTROINTESTINAL INFECTION; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOTHERAPY; INTERMETHOD COMPARISON; INTRAVENOUS IMMUNOGLOBULIN REPLACEMENT; LETTER; LOWER RESPIRATORY TRACT INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SUBCUTANEOUS IMMUNOGLOBULIN REPLACEMENT; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; AGAMMAGLOBULINEMIA; AGED; B LYMPHOCYTE; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PATHOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGAMMAGLOBULINEMIA; AGED; B-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; INFUSIONS, SUBCUTANEOUS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RITUXIMAB; TREATMENT OUTCOME;

EID: 84963647521     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.04.001     Document Type: Letter

References (6)

1. Compagno N., Malipiero G., Cinetto F., Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia. Front. Immunol. 2014, 5:626. 10.3389/fimmu.2014.00626.
2. Lingman-Framme J., Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. Drugs 2013, 73:1307-1319. 10.1007/s40265-013-0094-3.
3. Berger M., Rojavin M., Kiessling P., Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. J. Clin. Immunol. 2011, 139:133-141. 10.1016/j.clim.2011.01.006.
4. Jolles S., Sleasman J.W. Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a practical approach. Adv. Ther. 2011, 28:521-533.
5. Abolhassani H., Sadaghiani M.S., Aghamohammadi A., Ochs H.D., Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis. J. Clin. Immunol. 2012, 32:1180-1192. 10.1007/s10875-012-9720-1.
6. Chapel H., Gardulf A. Subcutaneous immunoglobulin replacement therapy: the European experience. Curr. Opin. Allergy Clin. Immunol. 2013, 13:623-629. 10.1097/ACI.0000000000000013.